CNX Therapeutics has appointed David Flint as Chief Corporate Development Officer (CCDO). Flint is an experienced M&A and corporate development executive with a strong track record of originating and executing complex transactions across the industry, most recently at UCB and Solvay. He brings broad international experience spanning EMEA, the Americas and Asia. In his new role, Flint will lead the company’s corporate development function, driving the identification and execution of strategic partnerships, licensing agreements and acquisitions that accelerate the company’s pan-European expansion. Flint joins CNX at a pivotal moment in the company’s European growth journey, bringing a distinguished track record in strategic development.

GC Therapeutics has appointed Stefan Irion as Chief Scientific Officer (CSO). Irion brings more than two decades of experience translating stem cell science into clinical stage therapeutics. In his role at GCTx, Irion will lead and direct the company’s research strategy as it advances its differentiated cell therapy pipeline towards the clinic. Irion joins GCTx from BlueRock Therapeutics (a wholly owned, independently operated subsidiary of Bayer), where he served as Chief Scientific Officer and a member of the Executive Committee. At BlueRock, he built and led a research organisation of approximately 60 scientists developing cell & gene therapies across multiple therapeutic areas. His appointment follows the recent addition of Kate Haviland as Board Chair.

AstronauTx has appointed Michelle Mellion as Chief Medical Officer (CMO). In her new role, Mellion will lead the clinical strategy and development activities. Mellion is a seasoned neurologist and clinical development leader, bringing more than two decades of experience across academia and the biotechnology industry. She has a strong track record of advancing innovative therapies for neurological and rare diseases, including neuromuscular disorders. Most recently, Mellion was CMO at PepGen and EveryONE Medicines, where she led clinical development efforts for oligonucleotide therapeutics and individualised medicines for ultra-rare conditions. Earlier in her career, she held positions at Biogen, Vertex Pharmaceuticals and Fulcrum Therapeutics.

LEO Pharma has appointed Matt Ferriday as General Manager for LEO Pharma UK. Matt joins the company from Ipsen Biopharma, where he held senior leadership roles across Rare Diseases and Neuroscience. A senior commercial leader with nearly two decades of experience, he has delivered high performance across in-country, regional and global roles, combining strategic leadership with strong operational execution. Driving sustainable growth, successful first-in-class launches and revitalising established franchises, Matt is passionate about addressing health inequity and making a positive impact on public health. Matt said: “My key priority is...working to deliver positive impact for people living with skin conditions.”

Helus Pharma has appointed Ken Kramer as Senior Vice President, Medical Affairs.

Kramer joins Helus with more than two decades of experience leading medical affairs strategy across neuroscience programmes, including global launch readiness, evidence generation and engagement with key opinion leaders. Most recently, he served as Vice President and Head of Medical Neuroscience at Bristol Myers Squibb.

At Karuna Therapeutics, as VP and Head of Medical Affairs, Kramer built and expanded medical capabilities during a period of significant organisational growth. Earlier in his career, Kramer spent more than a decade leading US psychiatry medical affairs teams at AbbVie and its predecessor organisations, contributing to multiple successful product launches.

Innovative Trials has appointed Anita Owen as its first-ever Chief Operating Officer. Owen will report directly to the company’s co-founder and CEO Kate Shaw. In her new role, Owen will lead the company’s operational strategy, bringing extensive experience in clinical operations and leading large global teams, particularly in the US and Asia-Pacific regions. Owen brings more than three decades of clinical research experience to the role, having begun her career as a Clinical Research Associate for Merck Sharp & Dohme (MSD) before moving into more senior management positions for organisations including Schering-Plough, Chugai Pharma Europe, INC Research and PRA Health Sciences. She also spent four years at Caidya, a US-based CRO.

Bowel Research UK has appointed Kathryn Pretzel-Shiels as CEO. Having led the charity as Interim CEO since October 2025, she now takes on the role on a permanent basis. Pretzel-Shiels has been closely involved with the charity since 2016, initially as a Trustee and later as Chair of the Fundraising, Marketing and Communications Committee, before becoming Interim CEO. She brings more than 30 years’ experience in international business and marketing leadership, having spent 28 years at American Express, working across three continents, and later serving as Marketing Director at PAUL, where she led brand, digital transformation and customer engagement. She has also held a number of board and advisory roles across the charity and not-for-profit sector.